Clinical Trials Logo

Filter by:
NCT ID: NCT03681184 Not yet recruiting - Clinical trials for Primary Hyperoxaluria Type 1 (PH1)

Phase 3 Study to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1

ILLUMINATE-A
Start date: September 26, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Lumasiran in Children and Adults with Primary Hyperoxaluria Type 1 (PH1).

NCT ID: NCT03677583 Recruiting - Clinical trials for Gastrointestinal Complication

Duckweed Intake Study

DIS
Start date: October 1, 2018
Phase: N/A
Study type: Interventional

The study aims to study the impact of frequent intake of 150-180 gram duckweed on gastrointestinal complaints and several other health related biomarkers. The study has a randomised parallel design. Two different treatments will be evaluated e.g. a 11-day intervention with duckweed based meals and a 11-day intervention with control/spinach meals. At the start and at the end of the intervention we will collect a blood sample and a urine samples. Questionnaires about gut complaints, stool consistency and frequency, wellbeing, health complaints or other adverse effects will be collected daily during intervention and up to two days after the intervention.

NCT ID: NCT03677050 Recruiting - Colorectal Cancer Clinical Trials

Effect of Individualized Patient Education Including Drinking Advice Using an App

Start date: September 14, 2018
Phase: N/A
Study type: Interventional

Study evaluating the effect of a personalized smart phone application in addition to standard care on bowel preparation scores, compared to standard care alone.

NCT ID: NCT03668236 Not yet recruiting - Septic Shock Clinical Trials

The Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care Trial

CLASSIC
Start date: November 2018
Phase: Phase 4
Study type: Interventional

The purpose of this trial is to assess patient important benefits and harms of IV fluid restriction vs. standard care fluid therapy in patients with septic shock.

NCT ID: NCT03668119 Not yet recruiting - Pan Tumor Clinical Trials

A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

CheckMate 848
Start date: September 28, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether nivolumab plus ipilimumab or nivolumab alone is effective and safe in the treatment of solid tumors with High Tumor Mutational Burden (TMB-H)

NCT ID: NCT03666013 Recruiting - Muscle Weakness Clinical Trials

Mitochondria and Muscle Health in Elderly

ELMIH
Start date: June 27, 2017
Phase:
Study type: Observational

The aim of this study is to characterize the relation between skeletal muscle mitochondrial metabolism and muscle health in elderly, physically compromised humans. To study this relation, we will perform a cross-sectional study in well-defined, distinct subject groups. Thus, to obtain insight in the relation between mitochondrial health and muscle function, we will not only compare subjects that differ in mitochondrial function (based on physical activity) but also select for subjects with high- versus low muscle function.

NCT ID: NCT03665168 Not yet recruiting - Clinical trials for Patients With Underlying Life-limiting Disease

A Multidimensional Strategy to Improve Quality of Life of Patients With Multiple Symptoms and Palliative Care Needs

MuSt-PC
Start date: September 2018
Phase:
Study type: Observational

A nationwide, cross-sectional study, to determine the prevalence of symptoms of patients in the palliative phase in various care settings will be performed within a set period of two working weeks in September 2018. The participating settings will be selected by a total of seven coordinators, one for each consortium of palliative care in the Netherlands. To identify common combinations of symptoms and for multidimensional screening the Utrecht Symptom Diary-4 Dimensional (USD-4D) and Utrecht Symptom Diary (USD), a Dutch instrument based on the Edmonton Symptom Assessment Scale, will be used. The current protocol focuses on the cross-sectional study.

NCT ID: NCT03664258 Recruiting - Clinical trials for Non-muscle-invasive Bladder Cancer

A Multi-National Study In Bladder Cancer Patients to Detect Recurrences After TURB (Trans-urethral Resection of the Bladder) Earlier With the Xpert Bladder Cancer Monitor Assay (ANTICIPATE X)

ANTICIPATE X
Start date: June 6, 2018
Phase:
Study type: Observational

Bladder cancer is the 5th most common cancer in Europe, with more than 151,000 new cases diagnosed in 2012 (4% of the total). Bladder cancer has the highest recurrence rate of any malignancy, often as high as 70% within 5 years of successful treatment. This high recurrence rate requires diligent and accurate monitoring as a means for early diagnosis and treatment. Considering the burden associated to repeated invasive cystoscopies, there is a need for robust but accurate tests for surveillance. In that prospect, urinary molecular tests have been developed although none were deemed adequate in the European clinical guidelines to replace cystoscopies. The Xpert Bladder Cancer Monitor Assay is a qualitative in vitro diagnostic test designed to monitor for the recurrence of bladder cancer in patients previously diagnosed with this cancer. The test provides a fast and accurate result, is non-invasive and easy to perform. The aim of this study is to assess the non-inferiority of the Xpert Bladder Cancer Monitor assay in detecting recurrences in comparison to cystoscopy in the follow-up of patients with low or intermediate risk non-muscle-invasive bladder cancer (NMIBC).

NCT ID: NCT03664011 Recruiting - Healthy Clinical Trials

A Study in Healthy Men to Test How BI 730357 is Processed by the Body

Start date: September 10, 2018
Phase: Phase 1
Study type: Interventional

The main objectives of the study are as follows: - To assess the mass balance recovery of [14C]-radioactivity in urine and faeces after a single oral dose of 50 mg BI 730357 BS (C-14) in healthy male subjects - To provide plasma, urine, and faecal samples for metabolite profiling and structural identification

NCT ID: NCT03662763 Completed - Clinical trials for Attention Deficit Disorder

Extended-release Guanfacine Hydrochloride in Children/Adolescents With Attention-deficit/Hyperactivity

SPD503-315
Start date: September 2011
Phase: Phase 3
Study type: Interventional

A study to evaluate the long term maintenance of efficacy of using Guanfacine Hydrochloride (SPD-503) for the treatment of ADHD in Children aged 6-17 years in Europe, Australia, Canada and the US.